Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
245.6 EUR | -0.14% | -.--% | -.--% |
Apr. 26 | Roche: positive CHMP opinion for Alecensa | CF |
Apr. 26 | Roche’s Lung Cancer Drug Alecensa Backed for Approval in EU | MT |
Performance
1 day | -0.14% | ||
5 years | +5.02% | ||
10 years | +17.85% |
Volumes
marketsBasic data
Highs and lows
Indicators
Sector Comparison - Other Pharmaceuticals
Name | Change | 5d. change | 1st Jan change | 1-year change | Capi. | |
---|---|---|---|---|---|---|
-0.14% | -.--% | -.--% | -.--% | 195B | ||
+1.19% | +0.99% | +25.83% | +87.91% | 661B | ||
+2.28% | +2.36% | +27.00% | +58.78% | 566B | ||
-0.46% | -1.20% | -6.76% | -10.34% | 352B | ||
+0.37% | +4.31% | +20.34% | +13.93% | 332B | ||
-4.58% | -4.08% | +3.00% | +7.22% | 283B | ||
-0.32% | +9.52% | +13.09% | +1.63% | 231B | ||
-0.56% | +4.64% | +5.46% | -2.03% | 200B | ||
+0.22% | +0.39% | -6.26% | +12.33% | 145B | ||
+0.55% | -2.31% | -11.77% | -34.43% | 144B | ||
-0.43% | +4.99% | +1.64% | -10.40% | 122B | ||
+0.34% | -8.34% | -12.59% | -33.66% | 90.92B | ||
+0.76% | +3.38% | +13.98% | +15.03% | 84.13B | ||
+0.23% | -2.01% | -19.24% | -21.70% | 81.58B | ||
-.--% | +1.73% | - | - | 63.66B | ||
+5.12% | +8.07% | +29.39% | +6.37% | 61.03B | ||
Average | +0.29% | +1.50% | +5.54% | +6.04% | ||
Weighted average by Cap. | +0.28% | +1.54% | +11.15% | +24.45% |
Historical data
Date | Opening | High | Low | End-of-day | Volume |
---|
Monthly variations
Annual change
2019 | +14.10% | ||
2018 | +2.07% | ||
2017 | -2.47% | ||
2016 | -16.04% | ||
2015 | +15.02% | ||
2014 | +10.70% | ||
2013 | +31.80% | ||
2012 | +17.05% | ||
2011 | +18.46% | ||
2010 | -7.00% | ||
2009 | +7.97% | ||
2008 | -6.50% | ||
2007 | -13.89% | ||
2006 | +8.33% | ||
2005 | +48.66% | ||
2004 | +5.59% | ||
2003 | +18.56% |
- Stock Market
- Equities
- ROG Stock
- RHO5 Stock
- Quotes Roche Holding AG